Vebreltinib for Previously Treated Astrocytoma, IDH -Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1–MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial

融合 化学 相(物质) 核磁共振 核医学 临床研究阶段 医学 分子生物学 核磁共振波谱 物理
作者
Zhaoshi Bao,Yake Xue,Yanhui Liu,Shouwei Li,Liang Wang,Yan Qu,Yonggao Mou,Rutong Yu,Jinsong Wu,Yu Yao,K. Shan Shan Shu,Guangyi Hu,Linbo Cai,Wenbin Li,Xiaoguang Qiu,Yunqian Li,Lei Zhang,Songtao Qi,Ying Ji,Chunxiao Ma
出处
期刊:癌症:英文版 卷期号:46: 0019-0019 被引量:3
标识
DOI:10.34133/cancomm.0019
摘要

Background: High-grade gliomas, including isocitrate dehydrogenase ( IDH )-mutant astrocytoma and IDH wild-type glioblastoma, have a poor prognosis and limited treatment options. The PTPRZ1–MET ( ZM ) fusion gene is a potential therapeutic target. This study evaluated vebreltinib, a highly selective, adenosine-triphosphate-competitive inhibitor of the mesenchymal–epithelial transition factor ( MET ), in patients with ZM -fusion-positive glioma. Methods: In this multicenter, open-label ZM FUsion GENe (FUGEN) trial, patients with previously treated astrocytoma, IDH -mutant, grade 4, or glioblastoma, IDH wild-type, harboring the ZM fusion were randomized in a 1:1 ratio to receive vebreltinib (300 mg orally twice daily) or control treatment (temozolomide or cisplatin plus etoposide) in 28-d cycles. The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety analyses. Results: Eighty-one patients (42 in the vebreltinib group and 39 in the control group) were included in the full analysis set. As of 2023 April 1, the median follow-up duration was 5.9 (range, 0.8 to 44.7) months in the vebreltinib group and 3.4 (range, 0.5 to 40.5) months in the control group. Median OS was significantly longer in the vebreltinib group than in the control group (6.3 months versus 3.4 months; hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.32 to 0.85; stratified log-rank P = 0.007). In the IDH -mutant subgroup, median OS was 7.7 months in the vebreltinib group and 3.3 months in the control group (HR, 0.48; 95% CI, 0.28 to 0.80; stratified log-rank P = 0.005). Among patients with a baseline tumor diameter of ≤3.0 cm, median OS was 32.5 months in the vebreltinib group versus 4.2 months in the control group (HR, 0.27; 95% CI, 0.07 to 1.06; stratified log-rank P = 0.046). Median PFS was also longer in the vebreltinib group (1.9 months versus 1.1 months; HR, 0.54; 95% CI, 0.33 to 0.88; stratified log-rank P = 0.012). The ORR was 9.5% with vebreltinib and 2.6% with control treatment. The incidence of grade ≥3 adverse events was comparable between groups, and no treatment-related deaths were reported. Conclusion: Vebreltinib significantly improved OS in patients with previously treated high-grade glioma harboring the ZM fusion, particularly in the subgroup with IDH -mutant astrocytoma, and the safety profile was manageable. Trial registration: This study was registered with the Chinese Drug Clinical Trial Registry ( ChinaDrugTrials.org.cn ) under the identifier, CTR20181664 (registration date: 2018 September 19).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Atlantis30发布了新的文献求助10
刚刚
KBB完成签到,获得积分10
1秒前
Akim的应助被dean采纳,获得10
1秒前
秋风的应助被小乔同学采纳,获得20
1秒前
SciGPT的应助被early采纳,获得10
2秒前
wy020829发布了新的文献求助10
2秒前
Lucia完成签到 ,获得积分10
3秒前
研友_VZG7GZ的应助被kiwi采纳,获得10
3秒前
ys发布了新的文献求助10
3秒前
778发布了新的文献求助10
4秒前
斯文败类的应助被耿春丽采纳,获得10
5秒前
5秒前
Viento完成签到 ,获得积分10
6秒前
John完成签到,获得积分10
6秒前
傢誠发布了新的文献求助10
6秒前
ys完成签到,获得积分10
7秒前
7秒前
8秒前
yhy完成签到,获得积分10
9秒前
JSM完成签到,获得积分10
9秒前
10秒前
10秒前
orixero的应助被Rr采纳,获得10
10秒前
李子完成签到,获得积分10
10秒前
Pxm发布了新的文献求助10
11秒前
12秒前
12秒前
吃花椒的汪汪完成签到,获得积分10
12秒前
Zaiye发布了新的文献求助10
13秒前
涓尘发布了新的文献求助10
13秒前
13秒前
14秒前
Drcai发布了新的文献求助10
15秒前
冰可乐完成签到,获得积分10
15秒前
N30发布了新的文献求助10
15秒前
Q_Q完成签到,获得积分10
16秒前
科研狗头军师完成签到 ,获得积分10
16秒前
阿泽完成签到,获得积分10
16秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963